Taylor Natalie, Bahunde Faith, Thompson Afton, Yu Jae-Sung, Jacobs William R, Letvin Norm L, Haynes Barton F, Lee Sunhee
Duke University School of Medicine, Human Vaccine Institute, Durham, NC, USA.
Clin Vaccine Immunol. 2012 Sep;19(9):1416-25. doi: 10.1128/CVI.00131-12. Epub 2012 Jul 11.
Mycobacteria have features that make them attractive as potential vaccine vectors. The nonpathogenic and rapidly growing Mycobacterium smegmatis can express both Mycobacterium tuberculosis antigens and heterologous antigens from other pathogens, and it has been used as a viable vector for the development of live vaccines. In order to further improve antigen-specific immunogenicity of M. smegmatis, we screened a random transposon mutant library for mutants displaying enhanced efficiency of protein secretion ("high secretors") and isolated 61 mutants showing enhanced endogenic and transgenic protein secretion. Sequence analysis identified a total of 54 genes involved in optimal secretion of insert proteins, as well as multiple independent transposon insertions localized within the same genomic loci and operons. The majority of transposon insertions occurred in genes that have no known protein secretion function. These transposon mutants were shown to prime antigen-specific CD8(+) T cell responses better than the parental strain. Specifically, upon introducing the simian immunodeficiency virus (SIV) gag gene into these transposon mutant strains, we observed that they primed SIV Gag-specific CD8(+) T cell responses significantly better than the control prime immunization in a heterologous prime/boost regimen. Our results reveal a dependence on bacterial secretion of mycobacterial and foreign antigens for the induction of antigen-specific CD8(+) T cells in vivo. The data also suggest that these M. smegmatis transposon mutants could be used as novel live attenuated vaccine strains to express foreign antigens, such as those of human immunodeficiency virus type 1 (HIV-1), and induce strong antigen-specific T cell responses.
分枝杆菌具有一些特性,使其成为有吸引力的潜在疫苗载体。非致病性且生长迅速的耻垢分枝杆菌能够表达结核分枝杆菌抗原以及来自其他病原体的异源抗原,并且已被用作开发活疫苗的可行载体。为了进一步提高耻垢分枝杆菌的抗原特异性免疫原性,我们筛选了一个随机转座子突变体文库,以寻找蛋白质分泌效率增强的突变体(“高分泌者”),并分离出61个显示内源性和转基因蛋白分泌增强的突变体。序列分析共鉴定出54个参与插入蛋白最佳分泌的基因,以及位于同一基因组位点和操纵子内的多个独立转座子插入。大多数转座子插入发生在没有已知蛋白质分泌功能的基因中。这些转座子突变体被证明比亲本菌株能更好地引发抗原特异性CD8(+) T细胞反应。具体而言,在将猿猴免疫缺陷病毒(SIV)gag基因引入这些转座子突变体菌株后,我们观察到在异源初免/加强免疫方案中,它们引发SIV Gag特异性CD8(+) T细胞反应的效果明显优于对照初免免疫。我们的结果揭示了体内诱导抗原特异性CD8(+) T细胞依赖于分枝杆菌和外来抗原的细菌分泌。数据还表明,这些耻垢分枝杆菌转座子突变体可作为新型减毒活疫苗菌株来表达外来抗原,如1型人类免疫缺陷病毒(HIV-1)的抗原,并诱导强烈的抗原特异性T细胞反应。